Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.81 USD
-0.04 (-2.16%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.81 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FBIO 1.81 -0.04(-2.16%)
Will FBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBIO
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
FBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum
New Strong Sell Stocks for May 16th
Other News for FBIO
Fortress Biotech’s Subsidiary Merges with Sun Pharma
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | FBIO Stock News
Wall Street Analysts Are Bullish on Top Healthcare Picks
Fortress Biotech Reports Q1 2025 Financial Highlights
Alliance Global Partners Sticks to Its Buy Rating for Fortress Biotech (FBIO)